Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Afinitor Goes To Panel Review With Trouble Areas For FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The Oncology Drugs Advisory Committee will review everolimus for certain advanced neuroendocrine tumors on April 12; the pivotal trial used progression-free survival and a crossover design, both areas that FDA has critiqued.

You may also be interested in...



Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor

The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.

Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor

The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.

Novartis Sales Grow at Double Digits, Helped by Generics, Vaccines

A diversified business allows the Swiss group to report a 14% sales rise for 2010, although pharma sales growth was just half that

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel